13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001017645
Total reported value
$2.9B
$2.9B
16 檔
78.2%
As reported in its official Q4 2024 Form 13F filing, General Atlantic, L.p.'s tracked investment portfolio stood at $2.9B with 16 total positions.
In Q4 2024, General Atlantic, L.p. adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including DLO, ALHC, ALKT) accounted for 78.2% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DLO | DLocal Limited | Stock-Other | 25.61% | -7.31% | — | |
| 2 | ALHC | Alignment Healthcare Inc | Stock-Other | 24.43% | — | — | |
| 3 | ALKT | Alkami Technology Inc | Stock-Other | 12.59% | +0.89% | -37.85% | |
| 4 | XPEV | XPeng Inc. | Stock-Other | 12.49% | -6.73% | — | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.77% | -2.50% | EXIT | |
| 6 | AKRO | Akero Therapeutics Inc | Stock-Other | 5.18% | — | — | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 5.14% | -2.77% | — | |
| 8 | EWCZ | European Wax Center Inc-a | Stock-Other | 3.11% | -3.53% | EXIT | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.36% | — | — | |
| 10 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.32% | — | — | |
| 11 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.24% | — | +13.98% | |
| 12 | RSKD | Riskified Ltd. | Stock-Other | 0.90% | -0.05% | — | |
| 13 | ✓ | Acelyrin Inc | Stock-Other | 0.30% | — | -6.73% | |
| 14 | ADAG | Adagene Inc-adr | Stock-Other | 0.27% | — | +1349.22% | |
| 15 | 5ZZ0 | Contextlogic Inc - A | Stock-Other | 0.15% | — | — | |
| 16 | GROV | Grove Collaborative Holdings | Stock-Other | 0.12% | -0.04% | +164.40% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DLO | DLocal Limited | +11.1% | — | Unchanged |
| 2 | ALHC | Alignment Healthcare Inc | +3.9% | — | Unchanged |
| 3 | 260 | Centessa Pharmaceuticals-adr | +1.4% | — | Unchanged |
| 4 | PHVS | Pharvaris N.V. | +1.2% | — | Unchanged |
| 5 | AKRO | Akero Therapeutics Inc | +0.9% | — | Unchanged |
| 6 | EWCZ | European Wax Center Inc-a | +0.6% | — | Unchanged |
| 7 | ADAG | Adagene Inc-adr | +0.3% | +1349.22% | Add |
| 8 | IMCR | Immunocore Holdings Plc-adr | +0.2% | — | Unchanged |
| 9 | RSKD | Riskified Ltd. | +0.2% | — | Unchanged |
| 10 | RPRX | Royalty Pharma plc | +0.2% | — | Unchanged |
| 11 | ✓ | Third Harmonic Bio Inc | +0.1% | +13.98% | Add |
| 12 | GROV | Grove Collaborative Holdings | +0.1% | +164.40% | Add |
| 13 | 5ZZ0 | Contextlogic Inc - A | +0.1% | — | Unchanged |
| 14 | ✓ | Acelyrin Inc | -0.1% | -6.73% | Trim |
| 15 | ALKT | Alkami Technology Inc | -1.3% | -37.85% | Trim |
| 16 | BLND | Blend Labs Inc-a | -2% | EXIT | Sold out |
| 17 | XPEV | XPeng Inc. | -2.6% | — | Unchanged |
| 18 | 8DT | Squarespace Inc - Class A | -14% | EXIT | Sold out |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 16 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top Position Liquidated / Trimmed
8DT
前期市值: $492.7M
During Q4 2024, General Atlantic, L.p.'s top holdings by market value included DLO (25.6%)、ALHC (24.4%)、ALKT (12.6%). The largest single position, DLO, represented 25.6% of total portfolio value.
In Q4 2024, General Atlantic, L.p. made 7 total portfolio adjustments, initiating 0 new buys, adding to 3 positions, trimming 2 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.